FindTrial
Sign In

The role of anticoagulant and thrombolitic in treatment of COVID patients

Evaluation of Tissue Plasminogen Activator (tPA) in comparition of anticoagulation for treatment of critical COVID 19 patient

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200515047456N1
Enrollment
15
Registered
2020-06-28
Start date
2020-06-17
Completion date
Unknown
Last updated
2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID 19. COVID-19, virus identified

Interventions

Intervention 1: Control group: Without placebo. Intervention 2: Intervention group: first intervention group, anticoagulant. ? the patients will be started on unfractional heparin. Blood sample will t

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 70 Years

Inclusion criteria

Inclusion criteria: COVID patients with P/F ratio less than 100 D.dimer more than 3000 without response to other medications

Exclusion criteria

Exclusion criteria: Active bleeding Platelet less than 30000 Without any contraindication for thrombolytic therapy

Design outcomes

Primary

MeasureTime frame
Improve of oxygenasion. Timepoint: From first to 6th days of study. Method of measurement: Arterial blood gas.;Improve SOFA score. Timepoint: From first to 6th days of study. Method of measurement: Questionnaire.;Improve compliance. Timepoint: From first to 6th days of study. Method of measurement: Ventilator parameter.;Decrease d.Dimer level. Timepoint: From first to 6th days of study. Method of measurement: Blood sample.—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarid Rashidi

Tabriz University of Medical Sciences

fr2652@yahoo.com+98 41 3336 4901

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026